P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

NCT06489340 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn due to patient enrollment challenges

Conditions

Diabetic Kidney Disease

Interventions

DRUG: 2HPβCD

Sponsor

ZyVersa Therapeutics, Inc.